1. Introduction {#sec1-molecules-22-01027}
===============

One of the United Nations' main focuses is to eradicate communicable diseases such as tuberculosis, which affect millions of people worldwide and causing more critical problems in countries with low- and middle-income. *Mycobacterium tuberculosis*, the causative agent of tuberculosis, is one of the most lethal human pathogens, further characterized by being strongly resistant to current treatments. Despite more than 100 years of research performed to date, the disease still kills about two million people every year around the world. According to the World Health Organization (WHO), a third of the world's population carries the infection in an inactive form known as latency \[[@B1-molecules-22-01027]\]. Our current inability to control the spread can be explained by the lack of an effective vaccine, multidrug-resistance \[[@B2-molecules-22-01027],[@B3-molecules-22-01027],[@B4-molecules-22-01027]\] and the great adaptability of *Mycobacterium tuberculosis*, which has great capacity for mutation, in different environments, it \[[@B5-molecules-22-01027],[@B6-molecules-22-01027],[@B7-molecules-22-01027],[@B8-molecules-22-01027],[@B9-molecules-22-01027],[@B10-molecules-22-01027]\].

In order to find new drug targets for tuberculosis treatment, in this study we analyzed the Protein Kinases (PKs) involved in tuberculosis. PKs, which are enzymes that catalyze the protein phosphorylation process, play an important role in controlling the proliferation and differentiation of eukaryotic cells in living organisms. One reason to investigate protein phosphorylation is that this rationalization represents an attractive drug target for a variety of diseases such as cancer \[[@B11-molecules-22-01027]\], Alzheimer's \[[@B12-molecules-22-01027]\], chronic inflammations \[[@B13-molecules-22-01027]\], etc. PKs present in the human body have been widely studied due to their use in therapeutic targets. However, not much is known about the PKs involved in tuberculosis. Therefore the binding sites associated to PKs A, B, and G of *Mycobacterium tuberculosis* are studied with a particular set of inhibitors to each PK.

The inhibitors used are a series of compounds of Pkn A reported by Sipos et al. \[[@B14-molecules-22-01027]\], of Pkn B reported by Székely et al. \[[@B15-molecules-22-01027]\], Loughheed et al. \[[@B16-molecules-22-01027]\], Chapman et al. \[[@B17-molecules-22-01027]\] and Naqvi et al. \[[@B18-molecules-22-01027]\], finally of PKn G reported by Sipos et al. \[[@B14-molecules-22-01027]\]. These ligands were used with the aim of obtaining new information about their stabilization in the active site.

The process of drug discovery is very complex and requires an interdisciplinary effort to design effective and commercially feasible drugs. In addition, the objective of drug design is to find a drug that can interact with a specific drug target and modify its activity. For this reason, we used a hybrid methodology to search new insights for tuberculosis treatment involving the application of Molecular Mechanics (MM) to protein treatment and consequently identifying the more active poses of the ligands involved in the anti-tuberculosis activity using computational techniques such as 3D pharmacophore searching and docking molecular \[[@B19-molecules-22-01027],[@B20-molecules-22-01027],[@B21-molecules-22-01027]\] to each PK.

With the goal of studying the selectivity of these inhibitors in the active site, we used considerations of Quantum Chemistry (QC), specifically the Molecular Quantum Similarity (MQS) field \[[@B22-molecules-22-01027],[@B23-molecules-22-01027],[@B24-molecules-22-01027],[@B25-molecules-22-01027]\] and chemical reactivity descriptors within the Density Functional Theory (DFT) framework \[[@B26-molecules-22-01027]\]. In previous works, the present author has reported his approaches to relate Molecular Mechanics with Quantum Chemistry (MM/QM) \[[@B27-molecules-22-01027]\]. Hopefully, this hybrid approach (MM/QM) provides new considerations about the interactions and selectivity of these ligands in the active sites of the PKs. Taking into account that selectivity is a very important aspect that is today widely studied in drug development with selective targets in diseases which are difficult to control like tuberculosis.

The final aspect of our work is to carry out a database screening using the 3D pharmacophores of PKn A, B and G reported on a database with anti-tuberculosis drugs, to find the compounds with affinity for the specific protein target associated with PKn A, B or G. To accomplish this we created a database using 183 anti-tuberculosis compounds reported by the Chibale group \[[@B28-molecules-22-01027],[@B29-molecules-22-01027],[@B30-molecules-22-01027],[@B31-molecules-22-01027],[@B32-molecules-22-01027]\]. The compounds reported by Chibale are racemic mixtures. Taking this into account, the chiral isomers were characterized from the computational viewpoint to find the specific isomers interacting with each characterized pharmacophore.

2. Results {#sec2-molecules-22-01027}
==========

The outcomes in this work are distributed as follows: (i) 3D pharmacophore searching for the protein kinases A, B and G, (ii) analysis of the 3D pharmacophores using molecular quantum similarity and chemical reactivity descriptors (selectivity analysis), and (iii) 3D pharmacophore-based database screening.

2.1. 3D Pharmacophore Searching: Mechanic Molecular Approach {#sec2dot1-molecules-22-01027}
------------------------------------------------------------

For the 3D pharmacophores analysis, we considered the classification given by Zuccotto's group \[[@B33-molecules-22-01027]\]. Zuccotto's work explains the active kinase conformation through the "gatekeeper door". In this sense, the compounds were classified as type I1/2 inhibitors; recognize the target kinases in the DFG "out" form for PKn A and DFG "in" for Pkn B, the Pkn G have DLG instead of DFG and is DLG "in". While developing the docking analysis, hydrogen bonds on the hinge zone and the non-covalent interactions near the "gatekeeper door", helix-αC, C-terminal and N-terminal, were taken into account. The non-covalent interaction involved backbone, side chain hydrogen bonding and aromatic-aromatic interactions. Ligands with high scores have combinations of these non-covalent interactions, while the ligands with lower scores have few to no interaction forces. Many of the top scoring ligands that form hydrogen bonds and aromatic-aromatic interactions with the amino acid residues, are close to the hinge zone.

The PKs A and B are transmembrane proteins, while the Pkn G is a cytosolic protein, therefore their active sites have different characteristics. The Pkn A and B consist of a transmembrane receptor with a tyrosine kinase domain, protruding into the cytoplasm. As for the Pkn G, the unique multidomain topology of Pkn G reveals a central kinase domain that is flanked by N- and C-terminal rubredoxin and tetratrico-peptide repeat domains. Directed mutagenesis suggests that the rubredoxin domain functions as a regulator of Pkn G kinase activity \[[@B34-molecules-22-01027]\], which was taken with its respective ligand to develop the docking analysis. To generate the pharmacophores the hypotheses with highest scoring were chosen, its features are shown in [Table 1](#molecules-22-01027-t001){ref-type="table"}.

In [Table 1](#molecules-22-01027-t001){ref-type="table"} we can see a good reproducibility of each hypothesis shown above 70% to the molecular groups studied, these hypotheses are shown and characterized in [Figure 1](#molecules-22-01027-f001){ref-type="fig"}, [Figure 2](#molecules-22-01027-f002){ref-type="fig"} and [Figure 3](#molecules-22-01027-f003){ref-type="fig"}.

In [Figure 1](#molecules-22-01027-f001){ref-type="fig"}, [Figure 2](#molecules-22-01027-f002){ref-type="fig"} and [Figure 3](#molecules-22-01027-f003){ref-type="fig"} are shown the interactions of the compounds **1** (Pkn A inhibitor), **7** (Pkn B inhibitor) and **23** (Pkn G inhibitor). Compound **1** presents three interactions on the hinge zone, while compound **7** presents two, and compound **23** also has three interactions. This criterion was crucial to define the actives poses and generate the hypothesis for each characterized pharmacophore. The results show the sites -H bond acceptor and -H bond donor on the hinge zone to all the ligands, establishing a structural model of the ligands on the active site with two or three interactions on this zone. With the focus to study the stabilization on the active site, we developed a study about chemical reactivity using DFT. The steric and electronic effects are characterized in terms of their chemical reactivity properties in the quantum chemistry context.

2.2. Selectivity Analysis: Quantum Chemistry Approach {#sec2dot2-molecules-22-01027}
-----------------------------------------------------

### 2.2.1. Molecular Quantum Similarity Study {#sec2dot2dot1-molecules-22-01027}

To analyze the steric and electronic effects, we calculate the Carbó indices to and the overlap and Coulomb similarity, the Carbó indices are restring on the interval (0, 1\] where 1 means self-similarity and 0 means null quantum similarity.

One election characteristic of the molecular groups, is that they must have the highest structural difference in order to generate 3D pharmacophores that may have the largest possible chemical information. This can be seen in [Table S6, see Supporting Information (SI)](#app1-molecules-22-01027){ref-type="app"}, where the majority of values corresponding to the structural similarity have low values, considering the fact that a good index of Carbó begins above 0.500. The highest comparison is between the compounds **2** and **3** with a value of 0.684 (see [Table S6](#app1-molecules-22-01027){ref-type="app"}) and an Euclidean distance of 4.191 ([Table S7, see SI](#app1-molecules-22-01027){ref-type="app"}). The lowest value is found in the comparison between the compounds **1** and **4**, with a value of 0.250 and an Euclidean distance of 6.317 (see [Table S7, in the SI](#app1-molecules-22-01027){ref-type="app"}). Compound **1** has the highest activity (pIC~50~ = −1.568). We can see high structure differences along this molecular set. To study these features from the electronic point of view, the Coulomb indices are shown in [Table S8, see SI](#app1-molecules-22-01027){ref-type="app"}.

The highest value using the Coulomb index is between the compounds **3** and **4** (0.902), and an Euclidean distance of 29.140 ([Table S9, in SI](#app1-molecules-22-01027){ref-type="app"}). However, the lowest value is between compounds **1** and **4** (0.779), and Euclidean distance of 40.699. To analyze the steric effects and electronic effects reported on the most active compound **1** we propose the convergence quantitative alpha (α) scales for steric effect and beta (β) for electronic effect ([Figure 4](#molecules-22-01027-f004){ref-type="fig"}), with the goal of studying the variability of the steric and electronic effects along the Pkn A inhibitors from the biological activity point of view.

In [Figure 4](#molecules-22-01027-f004){ref-type="fig"} we can see the variability in the steric and electronic effects with the Carbó indices of the most active compound **1**. For this compound the highest similarity is with compound **2** (0.798) using the Coulomb operator (electronic effect) and with compound **3** (0.369) using the Dirac delta (steric effect).

For the Pkn B inhibitors, we can see the Carbó index in [Tables S10--S13](#app1-molecules-22-01027){ref-type="app"}. For the overlap similarity, the highest comparison is between compounds **10** and **12** with a value of 0.832 (see [Table S10](#app1-molecules-22-01027){ref-type="app"}) and Euclidean distance of 2.512 (see [Table S11](#app1-molecules-22-01027){ref-type="app"}). The lowest value is obtained in the comparison between the compounds **10** and **16** with a value of 0.234 and Euclidean distance of 6.584 (see [Table S11 in the SI](#app1-molecules-22-01027){ref-type="app"}). Among these Pkn B inhibitors, the compound with highest activity is **11** with pIC~50~ = 1.638, it has the highest structural difference with the compound **10** with a value of 0.741 ([Table S10](#app1-molecules-22-01027){ref-type="app"}) and Euclidean distance of 3.241 ([Table S11](#app1-molecules-22-01027){ref-type="app"}). The lowest structural difference for compound **7** is with compound **11** with a value of 0.388 and Euclidean distance of 4.825. To analyze the electronic effects, we calculated the Carbó indices ([Table S12](#app1-molecules-22-01027){ref-type="app"}) using the Coulomb operators. The highest value in the Carbó index is obtain in the comparison between compounds **10** and **11** with the value 0.961 and Euclidean distance of 14.026 (see [Table S13](#app1-molecules-22-01027){ref-type="app"}). The lowest value is obtained between the compounds **9** and **13** with a value of 0.589 and Euclidean distance of 43.709. To analyse the steric effects and electronic effects on the most active compound **11**, we can see the alpha (α) and beta (β) scales in [Figure 5](#molecules-22-01027-f005){ref-type="fig"}, to study the variability of the steric and electronic effects along the Pkn B inhibitors from the biological activity viewpoint.

In [Figure 5](#molecules-22-01027-f005){ref-type="fig"} we can see the variability of the steric and electronic effects with the Carbó indices of the most active compound **11**. In both scales, compound **10** has the highest similarity and compound **16** has the lowest. These scales show how the chemical diversity selected can have influence on the biological activity, and also on the molecular space of the reported pharmacophore.

On the other hand, to the Pkn G inhibitors, the steric effects are shown in [Table S14, see SI](#app1-molecules-22-01027){ref-type="app"}. In general, for this molecular group we obtained high values in the Carbó index of overlap; this fact is consistent with the common structural nucleus for this particular group. The highest value of overlap Similarity is obtained in the comparison between compounds **23** and **24** with the value of 0.993 and Euclidean distance of 0.492 (see [Table S15](#app1-molecules-22-01027){ref-type="app"}), while the lowest value is obtained in the comparison between compounds **20** and **27** with a value of 0.532 and Euclidean distance of 4.556. These values show that the chemical diversity for this particular group is restricted with respect to the chemical diversity offered by the Pkn B inhibitors.

In general, the Coulomb indices show Carbó indices above of 0.900 (see [Table S16](#app1-molecules-22-01027){ref-type="app"}). The highest value is obtained in the comparison between compounds **23** and **24** with a value of 0.999 and Euclidean distance of 1.246 (see [Table S17, SI](#app1-molecules-22-01027){ref-type="app"}). The lowest value is obtained between compounds **24** and **27** with a value of 0.910 and Euclidean distance of 22.609. To analyze the variability of the steric and electronic effects on the biological activity, the alpha (α) and beta (β) scales are shown in [Figure 6](#molecules-22-01027-f006){ref-type="fig"}.

[Figure 6](#molecules-22-01027-f006){ref-type="fig"} shows the variability of the steric and electronic effects on the biological activity of compound **26**, the most active in this molecular group. In both scales, compound **19** has the highest structural and electronic similarity with compound **26**.

On the other hand, in the analyses for the Pkn A, B and G inhibitors, the highest values were obtained using the Carbó Coulomb index. Taking into account these facts, we can say that the electronic effects have higher effect that the steric effects in the stabilization of these compounds in the active site associated to the Pkn A, B and G. With the aim to explore these outcomes a study on the chemical reactivity using global and local reactivity descriptors is developed in the DFT context.

### 2.2.2. Chemistry Reactivity Study {#sec2dot2dot2-molecules-22-01027}

To study the electronic effects reported by the Carbó indices in the previous section, we calculated the global reactivity indices such as chemical potential, hardness, softness, electrophilicity (see [Table 2](#molecules-22-01027-t002){ref-type="table"}, [Table 3](#molecules-22-01027-t003){ref-type="table"} and [Table 4](#molecules-22-01027-t004){ref-type="table"}), and local as the Fukui functions in order to analyze the stabilization and interactions of these compounds in the active site.

In [Table 2](#molecules-22-01027-t002){ref-type="table"}, compound **1** has the lowest chemical potential (−4.124 eV), hardness (3.839 eV), softness (0.261 eV^−1^) and the highest electrophilicity (2.215 eV). This electrophilicity value can be related with the highest biological activity for this series, compound pIC~50~ = −1.568. Compound **1** shows the highest electronic and structural similarity when it is compared with compound **2** (0.787) and (0.369) (see [Figure 4](#molecules-22-01027-f004){ref-type="fig"}). Therefore, an electronic parameter such as the electrophilicity can be important in the stabilization of these anti-tuberculosis compounds in the active site. [Table 3](#molecules-22-01027-t003){ref-type="table"} shows the reactivity values to Pkn B inhibitors.

In [Table 3](#molecules-22-01027-t003){ref-type="table"}, compound **12** has the highest chemical potential and hardness with a value of −2.769 eV and 5.888 eV. Consequently, with these values this compound has the lowest softness (S = 0.170 eV^−1^) and electrophilicity (ω = 0.651 eV). These values are consistent with the lowest biological activity of this compound (pIC~50~ = −1.200). On the other hand, the highest values of softness and electrophilicity correspond to compound **16**, S = 0.275 eV^−1^ and ω = 1.721 eV. This compound shows the highest steric and electronic effects when is compared with the most active compound **11**, with a Carbó index of overlap 0.327 and Coulomb index of 0.733 (see [Figure 5](#molecules-22-01027-f005){ref-type="fig"}), therefore the steric and electronic effects large can have influence in the stability of such compounds, in the active site and consequently these aspects show low biological activity from experimental point of view. To analyze the chemical reactivity associated to the Pkn G inhibitors, we can consider their global indices listed in [Table 4](#molecules-22-01027-t004){ref-type="table"}.

In [Table 4](#molecules-22-01027-t004){ref-type="table"} we can see the values of electrophility (1.500 eV) and softness (0.229 eV^−1^) of compound **26**. These values are consistent with the highest biological activity to this compound (pIC~50~ = 2.000). However, the lowest values of electrophility and softness are found in compound **18** with 1.363 eV and 0.196 eV^−1^. Compound **18**'s values are related to the steric and electronic effects, quantified by the Carbó index of overlap 0.651 and Coulomb index of 0.960, with respect to the most active compound of this series compound **26** ([Figure 6](#molecules-22-01027-f006){ref-type="fig"}). Therefore, for this molecular group, the high biological activity may be related to the ability of the inhibitors, to receive electrons from the external environment. The stabilization can be determined by the retro-donor process on the hinge zone.

### 2.2.3. Local Reactivity Study {#sec2dot2dot3-molecules-22-01027}

To quantify the molecular interactions and selectivity of the Pkn A, B and G inhibitors, we calculated the Fukui functions **f(r) ^−,+,0^** on the most active compounds **1** of Pkn A, **7** of Pkn B and **23** of Pkn G. The most significant values of these functions are shown in [Figure 7](#molecules-22-01027-f007){ref-type="fig"}, [Figure 8](#molecules-22-01027-f008){ref-type="fig"} and [Figure 9](#molecules-22-01027-f009){ref-type="fig"}.

In [Figure 7](#molecules-22-01027-f007){ref-type="fig"} we can see the interactions of N43 (f(r)^−^:0.022) with GLY 100, N33 (f(r)^−^:0.117) and N32 (f(r)^−^:0.047) with the VAL 98. The sites with affinity to nucleophilic attack are of the oxygen atoms (O12 (f(r)^+^:0.185) and O13 f(r)^+^:0.183) and on the nitrogen atom f(r)^+^:0.220. Finally, the site with neutral affinity is of the oxygen atom O12 (f(r)^0^:0.093) these interactions are responsible for the stabilization of the hinge zone and of the active site for these anti-tuberculosis compounds (see [Figure 1](#molecules-22-01027-f001){ref-type="fig"}).

[Figure 8](#molecules-22-01027-f008){ref-type="fig"} shows the Fukui functions f(r)^−^ of the nitrogen atoms N12 (0.131), responsible for the hydrogen bond donor, and N11 (0.193) responsible for the acceptor site on the hinge zone. The other nitrogen atom, N5, besides showing a high f(r)^−^ = 0.225, shows a f(r)^0^ = 0.1138, representing that it can have either susceptibility to electrophilic attack, or toward neutral species. Therefore, this N5 can be crucial for the stabilization in the active site. The most sensitive values in the Fukui functions f(r)^+^ are shown on the carbon atoms C26 and C28, with values of 0.1173 and 0.1105. These values show the most susceptible zone to nucleophilic attacks. We can appreciate the nature of the molecular behaviour associated with the Pkn B inhibitors, and the type of stabilization that can happen on the active site. To know the nature of the chemical selectivity associated with the Pkn G inhibitors, is to know the Fukui functions of compound **23**.

[Figure 9](#molecules-22-01027-f009){ref-type="fig"} shows the Fukui functions f(r)^+,0^ of the nitrogen atom N13, with values of 0.0304 and 0.0221. These values justify the interactions between the nitrogen atom N13 and the residues Ile 292 and Glu 233 on the hinge zone (one interaction of nucleophilic character and another of neutral nature). Another important interaction is between the oxygen atom O12 and the residue Val 235, which can be related to the value of f(r)^+^ = 0.0688.

The values of f(r)^−^ relevant are shown in the carbon atoms C8 and C3 with 0.109 and 0.116, representing the areas susceptible to electrophilic attacks. In general, these values show the Fukui functions and the molecular behaviour of these Pkn G inhibitors. Compound **23** can also have intramolecular hydrogen bonds, that may be important in the stabilization of the active site. We can see the nature of the selectivity and the interactions of Pkn G inhibitors and how they can interact with the residues on the hinge zone (see [Figure 3](#molecules-22-01027-f003){ref-type="fig"}).

2.3. 3D Pharmacophore-Based Database Screening on the Chibale's Database (CD) {#sec2dot3-molecules-22-01027}
-----------------------------------------------------------------------------

The database screening \[[@B35-molecules-22-01027]\] is carried out using the Chibale database (see [SI](#app1-molecules-22-01027){ref-type="app"}), with the pharmacophores reported in [Figure 1](#molecules-22-01027-f001){ref-type="fig"}, [Figure 2](#molecules-22-01027-f002){ref-type="fig"} and [Figure 3](#molecules-22-01027-f003){ref-type="fig"}, to determine the compounds that can have affinity to each pharmacophores. The CD was created with 183 compounds \[[@B28-molecules-22-01027],[@B29-molecules-22-01027],[@B30-molecules-22-01027],[@B31-molecules-22-01027],[@B32-molecules-22-01027]\] (see [SI](#app1-molecules-22-01027){ref-type="app"}) and resulted in the following; 60 compounds have affinity with the Pkn A pharmacophore, 50 have affinity with the Pkn B, and other group of 30 compounds presented affinity with the Pkn G pharmacophore. These respectively affinities are shown in [Table 5](#molecules-22-01027-t005){ref-type="table"} and Table 7 through matching properties such as QPpolz: Predicted polarizability in Å^3^, SASA: Total Solvent-accessible Surface are in Å^2^, FOSA: Hydrophobic component of the SASA (saturated carbons and attached hydrogen), FISA: Hydrophilic component of the SASA (SASA on N, O and H on heteroatom), PISA: Pi (carbon and attached hydrogen) component of the SASA and finally WPS: Weakly polar component of the SASA (halogens, P and S).

In [Table 5](#molecules-22-01027-t005){ref-type="table"} and [Table 6](#molecules-22-01027-t006){ref-type="table"} we can see the 60 compounds matching the Pkn A pharmacophore. 50 compounds matching Pkn B, and 30 compounds with affinity to the Pkn G. In these tables there are also compounds with affinities to Pkn A, B and G simultaneously, compounds only with affinity to Pkn B and G, and finally compounds with only affinity to the Pkn A and B pharmacophores. The Tables predicted that polarizability values are into the recommended ranges for 95% of known drugs (13.0 to 70.0). On the other hand, the volume V~mol~ (the total volume of molecule enclosed by solvent-accessible molecular surface, in Å^3^ (probe radius 1.4 Å)) and the globularity descriptor Glob = (4πr^2^ )/Smol, where r is the radius of the sphere whose volume is equal to the molecular volume, are also in the recommended ranges (V~mol~: 500 to 2000 Å^3^) and (Glob: 0.75 to 0.95) \[[@B36-molecules-22-01027],[@B37-molecules-22-01027],[@B38-molecules-22-01027],[@B39-molecules-22-01027],[@B40-molecules-22-01027],[@B41-molecules-22-01027],[@B42-molecules-22-01027],[@B43-molecules-22-01027],[@B44-molecules-22-01027]\].

In [Table 7](#molecules-22-01027-t007){ref-type="table"} we can see that the *R* and *S* isomers of compound **61** only present affinities to the pharmacophore Pkn G. Other important properties are the predicted skin permeability (Qlog K~p~) and the number of likely metabolic reactions (\#metab). These properties also are in the recommended range (Qlog K~p~: −8.0 to −1.0) \[[@B45-molecules-22-01027],[@B46-molecules-22-01027]\] and (\#metab: 1 to 8) \[[@B36-molecules-22-01027],[@B37-molecules-22-01027],[@B38-molecules-22-01027],[@B39-molecules-22-01027],[@B40-molecules-22-01027],[@B41-molecules-22-01027],[@B42-molecules-22-01027],[@B43-molecules-22-01027],[@B44-molecules-22-01027]\]. The results of this database screening may be helpful to characterize, from an experimental point of view, the *R* and *S* isomers, which is the goal of this work. We hope that this information can provide insights about the stereoisomers for a specific target Pkn A, B or G. To assess the ligands reported by the database screening, we used docking molecular with the structural model generated by the 3D pharmacophores, in order to verify the interaction of these ligands on the active site in each protein kinase.

3. Materials and Methods {#sec3-molecules-22-01027}
========================

The molecular dataset used in this study was taken from the literature as follow: four Pkn A inhibitors reported by Sipos et al. \[[@B14-molecules-22-01027]\], 13 Pkn B inhibitor selected from the works of Székely et al. \[[@B15-molecules-22-01027]\], Lougheed et al. \[[@B16-molecules-22-01027]\], Chapman et al. \[[@B17-molecules-22-01027]\] and Naqvi et al. \[[@B18-molecules-22-01027]\] and 10 Pkn G inhibitors reported by Sipos et al. \[[@B14-molecules-22-01027]\]). In this molecular dataset we considered structural diversity and uniform distribution of IC~50~. Logarithmic IC~50~ (μM) (pIC~50~ = −log IC~50~) was employed as a dependent variable instead of IC~50~. The pIC~50~ values of inhibition of the compounds are shown in [Table 8](#molecules-22-01027-t008){ref-type="table"} for Pkn A, [Table 9](#molecules-22-01027-t009){ref-type="table"} for Pkn B and [Table 10](#molecules-22-01027-t010){ref-type="table"} for Pkn G.

3.1. System Preparation to the Molecular Mechanic (MM) Approach {#sec3dot1-molecules-22-01027}
---------------------------------------------------------------

The crystal structure of PKn A (PBD code: 4OW8 \[[@B47-molecules-22-01027]\]), B (PBD code: 1O6Y \[[@B48-molecules-22-01027]\]) and PKn G (PBD code: 2PZI \[[@B34-molecules-22-01027]\]) was prepared using Schrödinger Suite 2014-1's Protein Preparation Wizard module \[[@B49-molecules-22-01027],[@B50-molecules-22-01027]\], which refines the protein structure and optimizes the hydrogen bond (H-bond) network. Protonation states were determined using PropKa utility at a physiological pH. This was followed by a restrained molecular minimization using the Impact Refinement (Impref) module \[[@B51-molecules-22-01027],[@B52-molecules-22-01027]\], with the heavy atoms restrained to remain within a root-mean-square deviation (RMSD) of 0.18 Å from the initial coordinates. The 3D molecular structures of the compounds were built using Maestro \[[@B53-molecules-22-01027]\] and optimized using a B3LYP (hybrid-GGA exchange-correlation functional) at 6-311++G (2d,2p) level of theory \[[@B54-molecules-22-01027],[@B55-molecules-22-01027]\] using Gaussian 09 \[[@B56-molecules-22-01027]\], the ionization/tautomeric states were predicted at physiological pH conditions using Epik \[[@B57-molecules-22-01027]\].

3.2. Docking Studies and Pharmacophore Research {#sec3dot2-molecules-22-01027}
-----------------------------------------------

Docking studies were carried out with Glide \[[@B58-molecules-22-01027]\], using the Standard Precision (SP) mode with default parameters. Docking grid was generated with default settings centered at the co-crystallized ligand. A scaling factor down to 0.8 for the van der Waals radii of nonpolar protein atoms was used to accommodate the fact that the protein structure will not be optimized to fit larger ligands such as the studied in this work. The Induced Fit Docking (IFD) workflow \[[@B59-molecules-22-01027],[@B60-molecules-22-01027]\] was employed to generate an alternative conformation of the receptor suitable to bind the studied ligands, by allowing the protein to undergo side-chain or backbone movements, or both, upon ligand docking. To develop the docking analysis we used protein-ligand complex molecular dynamics simulation of 25 ns in vacuo using GROMOS11 force field set, implemented through Gromacs 5.1.2 \[[@B61-molecules-22-01027],[@B62-molecules-22-01027]\], to analyze the stability of each protein-ligand complex.

Finally, for the pharmacophore research we compared all the poses of the most and less active ligands for each congeneric family (PKn A, B and G), taking into account the extent of residue movement generated by the IFD calculation. The most energetically favourable conformation was selected by the best pose of each compound for further analysis, also ensuring that it exhibited interactions with the "hinge" residues of the PKs (i.e., Donor-Acceptor-Donor, DAD system). The pharmacophore research was carried out with Phase 3.7 \[[@B63-molecules-22-01027]\] using four pharmacophore features: Hydrogen bond acceptor (A), Hydrogen bond donor (D), Hydrophobic group (H) and Aromatic ring (R); the pharmacophores of the best ligand poses in the active sites of the PKn A, B and G were examined and we chose the hypothesis with the highest score.

4. Theoretical and Computational Details to the Quantum Chemistry Approach {#sec4-molecules-22-01027}
==========================================================================

In this work, with the goal of studying the inhibitor from the quantum chemistry point of view, we used the MQS field and chemical descriptors within the DFT context, to analyze the group correlation and look for the facts that can determine the anti-tuberculosis activity of the Pkn A, B and G inhibitors considered.

4.1. Molecular Quantum Similarity: Steric and Electronic Effects Study {#sec4dot1-molecules-22-01027}
----------------------------------------------------------------------

The similarity indices were introduced by Carbó and co-workers (see reviews on quantum similarity of \[[@B24-molecules-22-01027],[@B25-molecules-22-01027],[@B64-molecules-22-01027],[@B65-molecules-22-01027],[@B66-molecules-22-01027]\]), and have been used to understand the steric and electronic effect on the molecular sets. The quantum similarity measure *Z~AB~* between compounds **A** and **B**, with electron density $\rho_{A}\left( \gamma_{1} \right)$ and $\rho_{B}\left( r_{2} \right)$ is defined, based on the idea of the minimizing of the expression for the Euclidean distance as:$$D_{AB}^{2} = \int^{}\left| {\rho_{A}\left( r \right) - \rho_{B}\left( r \right)} \right|^{2}dr = \int\left( {\rho_{A}\left( r_{1} \right)} \right)^{2}\ dr_{1} + \int\left( {\rho_{B}\left( r_{2} \right)} \right)^{2}\ dr_{2} - 2\int\rho_{A}\left( r_{1} \right)\left( r_{2} \right)dr_{1}dr_{2} = Z_{AA} + Z_{BB} - 2Z_{AB}$$

Overlap integral involving the *Z~AB~* between the electronic density of the compound **A** and **B**, *Z~AA~* and *Z~BB~* are the self-similarity of compounds **A** and **B** \[[@B64-molecules-22-01027],[@B65-molecules-22-01027],[@B66-molecules-22-01027]\]. The most common quantum similarity index is the one generalized by the cosine, introduced by Carbó et al. \[[@B64-molecules-22-01027],[@B65-molecules-22-01027],[@B66-molecules-22-01027]\]. This index can be expressed mathematically as:$$I_{AB} = \frac{\int^{}\rho_{A}\left( r_{1} \right)\rho_{B}\left( r_{2} \right)dr_{1}dr_{2}}{\sqrt{\int^{}\left( {\rho_{A}\left( r_{1} \right)} \right)^{2}dr_{1}\int^{}\left( {\rho_{B}\left( r_{2} \right)} \right)^{2}\ dr_{2}}}$$ or using the elements of *Z* in an operator (Ω):$$I_{AB} = \frac{Z_{AB}\left( \mathrm{\Omega} \right)}{\sqrt{Z_{AA}\left( \mathrm{\Omega} \right)Z_{BB}\left( \mathrm{\Omega} \right)}}$$

In Equation (3), the index is mathematically defined in the interval (0, 1) where 1 is self-similarity, and where only the measures of "shape similarity" are included. Another alternative is the Hodgkin-Richards index \[[@B67-molecules-22-01027]\], which appears naturally when using the arithmetic mean and can be defined mathematically as:$$I_{AB} = \frac{2Z_{AB}\left( \mathrm{\Omega} \right)}{Z_{AA}\left( \mathrm{\Omega} \right) + Z_{BB}\left( \mathrm{\Omega} \right)}$$

This is (Ω) an operator for the measurement of quantum similarity. The Equation (4) shows another way to make Quantum Similarity Measures (QSM), but recent published work has shown that in fact, it is just an Euclidean distance, like shown in Equation (1) \[[@B68-molecules-22-01027]\].

A simple way to make Quantum Similarity Measure (QSM) \[[@B22-molecules-22-01027],[@B23-molecules-22-01027],[@B24-molecules-22-01027]\] involving two density functions, in the most usual form:$$Z_{AB}\left( \mathrm{\Omega} \right) = \iint\rho_{A}\left( r_{1} \right)\mathrm{\Omega}\left( {r_{1},r_{2}} \right)\rho_{B}\left( r_{2} \right)dr_{1}dr_{2}$$

In this equation $\rho_{A}\left( r_{1} \right)$ and $\rho_{B}\left( r_{2} \right)$ are the density functions to quantum objects ***A*** and ***B***, while $\mathrm{\Omega}\left( {r_{1},r_{2}} \right)$ is a positive define weight operator. When the operator is chosen as the Dirac Delta function: $\delta\left( {r_{1} - r_{2}} \right)$ we obtain overlap similarity measure, while Coulomb Similarity Measure appears when choosing: $\left| {r_{1} - r_{2}} \right|^{- 1}$ These two operators are the most popular for similarity comparisons between molecules.

4.2. Molecular Alignment {#sec4dot2-molecules-22-01027}
------------------------

To carry out the quantum similarity measures is an important optimal molecular alignment. As the integrals attached to the QSM produce, real positive defined results, the relative position problem can be addressed through a maximal QSM. For an overlap QSM, this situation can be expressed by means of the equation:$$\max\limits_{T;\varnothing}Z_{AB}\left( {T;\varnothing} \right) = \max\limits_{T;\varnothing}\int^{}\rho_{A}\left( r \right)\rho_{B}\left( r \middle| T;\varnothing \right)dr$$

In this equation, is implicitly supposed that $\rho_{B}\left( r \right)$ is translated and rotated by six possible ways, (T;φ) and are shown as explicit parameters in this integral \[[@B22-molecules-22-01027],[@B23-molecules-22-01027],[@B24-molecules-22-01027],[@B69-molecules-22-01027]\]. This principle is used by the Topo Geometrical Superposition Algorithm (TGSA) \[[@B70-molecules-22-01027]\] and is the program used in this study to calculate the Carbó indices using Equation (2).

4.3. Chemical Reactivity Descriptors: Selectivity Study {#sec4dot3-molecules-22-01027}
-------------------------------------------------------

The global reactivity descriptors are defined within the DFT framework and were interpreted by Parr and coworkers \[[@B71-molecules-22-01027],[@B72-molecules-22-01027],[@B73-molecules-22-01027],[@B74-molecules-22-01027],[@B75-molecules-22-01027],[@B76-molecules-22-01027],[@B77-molecules-22-01027],[@B78-molecules-22-01027]\]. The chemical potential can be written mathematically in terms of the energy of an electron in the frontier molecular orbitals (Higher Occupied Molecular Orbital) HOMO and (Lowest Unoccupied Molecular Orbital) LUMO as:$$\mathsf{\mu} \approx \frac{\varepsilon_{L} + \varepsilon_{H}}{2}$$

From (8), one can obtain quantitative expression for the chemical hardness (*η*) \[[@B79-molecules-22-01027],[@B80-molecules-22-01027],[@B81-molecules-22-01027],[@B82-molecules-22-01027],[@B83-molecules-22-01027]\], meaning that the opposition of the system to distort the electron cloud and mathematically can be written as:$$\eta \approx \varepsilon_{L} - \varepsilon_{H}$$

On the other hand, we have the global electrophilicity (ω) introduced by Parr et al. \[[@B84-molecules-22-01027]\], which is a measure of the stabilization energy of the system when it is saturated by electrons from the external environment and represented mathematically as:$$\mathsf{\omega} = \frac{\mu^{2}}{2\eta}$$

The Fukui function ($f\left( r \right)$) was one of the descriptors used in this work and defined as:$$f\left( r \right) = \left( \frac{\partial\rho\left( r \right)}{\partial N} \right)_{V} = \left( \frac{\partial\mu}{\partial V\left( r \right)} \right)_{N}$$

Due to that $f\left( r \right)$ is discontinuous at integer values of 𝑁. There are three types according to Fukui et al., *f*^+^ which contain information on the reactivity local of nucleophilic attack, *f*^−^ (11) which does the same for an electrophilic attack. And finally *f*^0^, that measures the reactivity towards neutral or radical agents \[[@B84-molecules-22-01027],[@B85-molecules-22-01027],[@B86-molecules-22-01027],[@B87-molecules-22-01027],[@B88-molecules-22-01027],[@B89-molecules-22-01027],[@B90-molecules-22-01027],[@B91-molecules-22-01027]\], using the condensation scheme on specific sites of the molecule to obtain the following Fukui indices \[[@B92-molecules-22-01027],[@B93-molecules-22-01027],[@B94-molecules-22-01027],[@B95-molecules-22-01027]\]:$${f_{x}^{+}\left( r \right) \approx \rho_{N + 1}^{x}\left( r \right) - \rho_{N}^{x}\left( r \right) \approx q_{x}\left( {N + 1} \right) - q_{x}\left( N \right)}{f_{x}^{-}\left( r \right) \approx \rho_{N}^{x}\left( r \right) - \rho_{N - 1}^{x}\left( r \right) \approx q_{x}\left( N \right) - q_{x}\left( {N - 1} \right)}{f_{x}^{0}\left( r \right) \approx \left\lbrack \frac{f_{x}^{+} + f_{x}^{-}}{2} \right\rbrack \approx \frac{\rho_{N + 1}^{x}\left( r \right) - \rho_{N - 1}^{x}\left( r \right)}{2} \approx \frac{q_{x}\left( {N + 1} \right) - q_{x}\left( {N - 1} \right)}{2}}$$

Hopefully using this equation scheme will help understanding the biological activity (selectivity) of the PKn A, B and G inhibitors studied from global and local point of view.

4.4. Creating the 3D Chibale's Database: Database Screening {#sec4dot4-molecules-22-01027}
-----------------------------------------------------------

Computational Aided Drug Design (CADD) is presently a key component in the process of drug discovery and development associated with the tuberculosis disease. It offers great promise to drastically reduce cost and time requirements. In a pharmaceutical context, database screening is normally regarded as the top CADD tool to screen large libraries of chemical structures, and reduce them to a key set of likely drug candidates regarding a specific protein target \[[@B96-molecules-22-01027],[@B97-molecules-22-01027]\].

In this work, the 3D Chibale database was created using 103 anti-tuberculosis compounds reported by the Chibale group \[[@B28-molecules-22-01027],[@B29-molecules-22-01027],[@B30-molecules-22-01027],[@B31-molecules-22-01027],[@B32-molecules-22-01027]\]. Each anti-tuberculosis compound was characterized taking account their chiral centers (chiral isomers), which leaves the final molecular group with 183 compounds (see [Tables S1--S5 in Supporting Information (SI)](#app1-molecules-22-01027){ref-type="app"}). This 3D database was created using the command line tools of Accompany Phase version 3.5, which is part of the Schrödinger Suite 2013 release \[[@B98-molecules-22-01027],[@B99-molecules-22-01027],[@B100-molecules-22-01027]\]. It was used to evaluate the pharmacophores to Pkn A, B and G reported, to identify the compound that may have affinity with these specific protein targets.

5. Conclusions {#sec5-molecules-22-01027}
==============

In conclusion, the 3D pharmacophore reported were selected according to the hypotheses with highest score (Acceptor: A1/A2/A3/Donor:D) of Pkn A and (A/A/D/aromatic ring:R) of Pkn B and G. The three 3D pharmacophores generated were characterized using the molecular quantum similarity field and reactivity descriptors supported in the DFT framework.

To develop the study of quantum similarity, we used the Carbó indices. Through these indices are proposed the convergence quantitative alpha (α) scale to steric effects and beta (β) to electronic effects with respect to the most active compound of each inhibitor set. In this analysis, the Carbó indices with the highest values are the Coulomb values. Considering that the electronic effects are more relevant than the steric, we develop a study using global reactivity descriptors such as Chemical Potential, Harness, Softness and the Fukui functions as local descriptor, to understand the interaction of these compounds in the active sites.

The conclusion regarding the chemistry reactivity of Pkn A inhibitors is that the electronic factors as the electrophilicity can be important in the stabilization of these anti-tuberculosis compounds. In the active site of Pkn B inhibitors, there are steric and electronic effects that can have a big influence in the stability of such compounds in the active site. Consequently these aspects show low biological activity from experimental point of view. Regarding Pkn G inhibitors, the high biological activity may be related to the ability of the inhibitors to receive electrons from the external environment. The stabilization can be determined by the retro-donor process on the hinge zone. In this order of ideas, the reactivity descriptors reported can be related to the experimental data.

Finally, the database screening was developed using the Chibale's Database created with 183 anti-tuberculosis compounds and using the Pkn A, B and G pharmacophores reported. We found 60 compounds with affinity to the Pkn A pharmacophore, 50 compounds for the PKn B and 30 compounds to the Pkn G. These predictions were tested with properties related such as **QPpolz**: Predicted Polarizability in Å^3^, **SASA**: total Solvent-Accessible Surface Are in Å^2^, **FOSA**: Hydrophobic component of the SASA (saturated carbons and attached hydrogen) and **WPS**: Weakly Polar Component of the SASA (halogens, P and S), among others. These properties related are within the recommended ranges for 95% of known drugs. In addition, the docking results for these ligands show the sites --H bond acceptor and --H bond donor, which are the characteristic interactions on the hinge zone in the active site, of each protein kinase studied.

A.M.-B. Thanks to CONICYT/FONDECYT through postdoctoral project No. 3150035 and to the drug discovery group of Professor Kelly Chibale, University of Cape Town, South Africa.

**Sample Availability:** Samples of the compounds are not available from the authors.

The Supplementary Materials following are available online.
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![(**a**) Hypotheses AAAD to Pkn A on the Compound **1**, pIC~50~ = −1.569; (**b**) Ligands interactions between Gly 100, Val 98, Lys 42, 143, Asn 146 and Asp 159 residues and finally (**c**) Ligands interactions between Val 98 and Gly 100 residues on the Hinge zone to the compound **1**. PKn A (PBD code: 4OW8).](molecules-22-01027-g001){#molecules-22-01027-f001}

![(**a**) Hypotheses AADR to Pk B on the Compound **7**, pIC~50~ = 1.066; (**b**) Zuccotto classification: type I1/2-Hinge Region/Back Pocket pharmacophore, DFG "in" Kinase (see Ref. \[[@B33-molecules-22-01027]\]) and ligand interactions between Val 95 residues in the Hinge zone with the compound **7**. Pkn B (PBD code: 1O6Y).](molecules-22-01027-g002){#molecules-22-01027-f002}

###### 

(**a**) Hypotheses AADR to Pk G on compound **23** (R isomer), pIC~50~ = 1.699; (**b**) Ligand interactions between Glu 233, Val 235 and Ile 292 residues in the hinge zone with compound **23**. PKn G (PBD code: 2PZI).
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![Convergence quantitative scales α to steric effects (overlap similarity) and β to electronic effects (coulomb similarity) for Pkn A inhibitors with respect to the most active compound **1**.](molecules-22-01027-g004){#molecules-22-01027-f004}

![Convergence quantitative scales α for steric effects (overlap similarity) and β for electronic effects (Coulomb similarity) for Pkn B inhibitors with respect to the most active compound **11**.](molecules-22-01027-g005){#molecules-22-01027-f005}

![Convergence quantitative scales α for steric effects (overlap similarity) and β for electronic effects (coulomb similarity) for Pkn G inhibitors with respect to the most active compound **26**.](molecules-22-01027-g006){#molecules-22-01027-f006}

![Local reactivity indices (Fukui functions) on the compound **1**, see [Figure 1](#molecules-22-01027-f001){ref-type="fig"}.](molecules-22-01027-g007){#molecules-22-01027-f007}

![Local reactivity indices (Fukui functions) on the compound **7**, see [Figure 2](#molecules-22-01027-f002){ref-type="fig"}.](molecules-22-01027-g008){#molecules-22-01027-f008}

![Local reactivity indices (Fukui functions) on the compound **23**, see [Figure 3](#molecules-22-01027-f003){ref-type="fig"}.](molecules-22-01027-g009){#molecules-22-01027-f009}
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###### 

Statistical data for the hypothesis of Pkn A, B and G, respectively.

  PKn A     Survival   Site    Vector   Volume   Matches
  --------- ---------- ------- -------- -------- --------------------
  AAAD \*   3.145      0.85    0.956    0.484    4 of 4 compounds
  ADRR      3.680      0.458   0.854    0.421    3 compounds
  AADR      3.845      0.569   0.548    0.401    3 compounds
  PKn B     Survival   Site    Vector   Volume   Matches
  AADR \*   4.316      0.93    0.992    0.627    9 of 13 compounds
  AADR      4.308      0.91    0.988    0.640    7 compounds
  DHRR      4.253      0.80    0.962    0.547    8 compounds
  PKn G     Survival   Site    Vector   Volume   Matches
  AADR \*   3.056      0.47    0.888    0.696    10 of 10 compounds
  AADR      2.466      0.46    0.753    0.257    10 compounds
  AADR      2.180      0.16    0.710    0.311    10 compounds

**\*** Hyphotheses selected.
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###### 

Global Chemical Reactivity Indices for Pkn A inhibitors. Chemical Potential (μ), Chemical Hardness (ƞ) and Electrophilicity (ω) in eV and Softness (S) in (eV)^−1^.

  Compound   C. Potential (μ)   C. Hardness (η)   Softness (S)   Electrophilicity (ω)
  ---------- ------------------ ----------------- -------------- ----------------------
  **1**      −4.124             3.839             0.261          2.215
  **2**      −3.485             3.543             0.282          1.714
  **3**      −3.418             3.959             0.253          1.476
  **4**      −3.491             3.154             0.317          1.932
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###### 

Global Chemical Reactivity Indices for Pkn B inhibitors. Chemical Potential (μ), Chemical Hardness (η) and Electrophilicity (ω) in eV and Softness (S) in (eV)^−1^.

  Compound   C. Potential (μ)   C. Hardness (η)   Softness (S)   Electrophilicity (ω)
  ---------- ------------------ ----------------- -------------- ----------------------
  **5**      −3.575             5.655             0.177          1.129
  **6**      −2.965             4.118             0.243          1.067
  **7**      −3.575             4.089             0.245          1.563
  **8**      −2.621             5.030             0.199          0.683
  **9**      −2.981             4.351             0.230          1.021
  **10**     −3.531             4.937             0.202          1.268
  **11**     −3.313             3.764             0.266          1.458
  **12**     −2.769             5.888             0.170          0.651
  **13**     −2.887             4.630             0.216          0.900
  **14**     −3.494             4.399             0.227          1.386
  **15**     −3.111             4.705             0.213          1.028
  **16**     −3.549             3.642             0.275          1.721
  **17**     −3.252             3.428             0.292          1.543
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###### 

Global Chemical Reactivity Indices for Pkn G inhibitors. Chemical Potential (μ), Chemical Hardness (η) and Electrophilicity (ω) in eV and Softness (S) in (eV)^−1^.

  Compound   C. Potential (μ)   C. Hardness (η)   Softness (S)   Electrophilicity (ω)
  ---------- ------------------ ----------------- -------------- ----------------------
  **18**     −3.730             5.103             0.196          1.363
  **19**     −3.386             3.940             0.254          1.455
  **20**     −3.905             5.127             0.195          1.487
  **21**     −3.622             4.471             0.224          1.467
  **22**     −3.731             4.473             0.224          1.556
  **23**     −3.745             4.478             0.223          1.566
  **24**     −4.131             4.651             0.215          1.835
  **25**     −3.241             4.407             0.227          1.198
  **26**     −3.623             4.375             0.229          1.500
  **27**     −3.611             4.490             0.223          1.459
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###### 

Properties related and selected from the virtual screening on the Chibale's Database (CB).

  Compound with Pkn A Affinity   R       *n*   QPpolz ^d^   SASA ^e^   FOSA ^f^   FISA ^g^   PISA ^h^   WPSA ^i^   Clog P
  ------------------------------ ------- ----- ------------ ---------- ---------- ---------- ---------- ---------- --------
  **CB ^a^-11 ^b^ RR ^c^′**      H       3     33.435       519.287    246.394    108.866    134.095    29.932     2.12
  **CB-11RS ′**                  H       3     33.444       519.272    263.242    77.672     149.322    29.035     2.12
  **CB-11SR \***                 H       3     32.996       509.874    250.606    107.808    124.503    26.957     2.12
  **CB-11SS \***                 H       3     33.785       524.334    265.154    85.176     149.124    24.881     2.12
  **CB-12RR ′**                  Br      3     35.103       548.141    246.203    108.886    86.116     106.937    3.12
  **CB-12RS ′**                  Br      3     35.102       548.265    263.252    77.672     101.105    106.237    3.12
  **CB-12SR ′**                  Br      3     34.852       533.186    249.293    105.638    76.888     101.367    3.12
  **CB-12SS \***                 Br      3     35.515       554.864    265.193    85.184     102.419    102.068    3.12
  **CB-13RR ′**                  I       3     35.500       553.805    246.169    108.885    85.600     113.151    3.38
  **CB-13RS \***                 I       3     35.055       542.675    250.252    106.173    78.136     108.114    3.38
  **CB-13SR ′**                  I       3     35.498       553.944    263.253    77.671     100.562    112.458    3.38
  **CB-13SS \***                 I       3     35.911       560.530    265.180    85.178     101.877    108.294    3.38
  **CB-14RR ′**                  F       3     33.723       528.294    246.429    108.875    96.135     76.855     2.40
  **CB-14RS \***                 F       3     33.510       515.890    249.540    107.362    85.703     73.284     2.40
  **CB-14SR ′**                  F       3     33.727       528.286    263.248    77.672     111.462    75.905     2.40
  **CB-14SS \***                 F       3     34.140       534.883    265.189    85.187     85.187     71.739     2.40
  **CB-15RR ′**                  Cl      3     34.752       543.124    246.230    108.883    86.801     101.210    2.97
  **CB-15RS \***                 Cl      3     34.511       528.669    249.320    105.938    77.560     95.851     2.97
  **CB-15SR ′**                  Cl      3     34.752       543.237    263.253    77.672     101.828    100.483    2.97
  **CB-15SS \***                 Cl      3     35.165       549.828    265.186    85.186     103.137    96.319     2.97
  **CB-16RR ′**                  CH~3~   3     35.277       549.512    331.983    108.869    78.728     29.933     2.62
  **CB-16RS\***                  CH~3~   3     34.849       538.256    333.659    105.147    72.444     27.006     2.62
  **CB-16SR ′**                  CH~3~   3     35.306       551.436    351.239    77.670     93.498     29.029     2.62
  **CB-16SS\***                  CH~3~   3     35.715       557.934    353.127    85.178     112.768    24.885     2.62
  **CB-17RR ′**                  NO~2~   3     35.116       556.139    245.355    204.840    76.018     29.927     2.16
  **CB-17RS \***                 NO~2~   3     34.684       544.945    250.325    198.137    69.525     26.958     2.16
  **CB-17SR ′**                  NO~2~   3     35.157       557.839    263.310    174.709    90.792     29.029     2.16
  **CB-17SS ′**                  NO~2~   3     34.555       548.924    242.772    205.494    70.921     29.737     2.16
  **CB-22RR ′**                  H       5     36.703       547.504    292.222    101.786    124.211    29.285     3.24
  **CB-22RS\***                  H       5     37.311       561.538    269.138    131.258    151.763    9.379      3.24
  **CB-22SR ′**                  H       5     36.593       545.737    297.895    97.651     122.486    27.705     3.24
  **CB-22SS\***                  H       5     37.288       558.397    290.577    105.866    137.393    24.561     3.24
  **CB-23RR ′**                  Cl      5     38.013       571.319    292.026    101.818    76.893     100.582    4.09
  **CB-23RS ′**                  Cl      5     38.624       585.586    269.148    131.276    104.292    104.292    4.09
  **CB-23SR \***                 Cl      5     38.638       587.477    314.807    77.673     95.413     99.584     4.09
  **CB-23SS \***                 Cl      5     38.182       578.661    287.071    124.580    95.665     71.345     4.09
  **CB-24RR ′**                  F       5     36.985       556.516    292.243    101.807    86.274     76.192     3.52
  **CB-24RS ′**                  F       5     37.595       570.571    269.155    131.263    113.869    56.283     3.52
  **CB-24SR ′**                  F       5     37.691       574.185    314.788    77.664     106.723    75.009     3.52
  **CB-24SS \***                 F       5     37.061       548.024    313.187    78.434     97.486     58.918     3.52
  **CB-25RR ′**                  Br      5     38.384       576.756    291.976    101.823    101.823    106.298    4.24
  **CB-25RS \***                 Br      5     38.799       586.992    267.539    128.972    104.130    86.352     4.24
  **CB-25SR ′**                  Br      5     38.987       592.508    314.806    77.674     94.692     105.336    4.24
  **CB-25SS \***                 Br      5     38.522       583.254    287.106    124.245    94.983     76.920     4.24
  **CB-26RR ′**                  I       5     38.781       582.399    291.923    101.820    76.160     112.495    4.50
  **CB-26RS \***                 I       5     39.003       590.994    269.419    128.332    100.816    92.427     4.50
  **CB-26SR ′**                  I       5     39.384       598.197    314.810    77.679     94.151     111.557    4.50
  **CB-26SS \***                 I       5     39.003       582.006    283.206    121.666    94.068     83.066     4.50

**^a^ CB**: Chibale's Database; **^b^** Numeration in the Chibale's Database (see [SI](#app1-molecules-22-01027){ref-type="app"}); **^c^** Chiral isomers: RR, RS, SR and SS; **^d^ QPpolz**: Predicted polarizability in Å^3^; **^e^ SASA**: Total Solvent-accessible Surface are in Å^2^; **^f^ FOSA**: Hydrophobic component of the SASA (saturated carbons and attached hydrogen); **^g^ FISA**: Hydrophilic component of the SASA (SASA on N, O and H on heteroatom); **^h^ PISA**: Pi (carbon and attached hydrogen) component of the SASA; **^i^ WPS**: Weakly polar component of the SASA (halogens, P and S); **\*** Compound with Pkn A, B and G affinity; **′** Compound with only Pkn A and B affinity.
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###### 

The virtual screening on Chibale's Database (CD).

  ---------------------------------- ---------------------------------- ---------------------------------- ------- ----------------- -------------
  ![](molecules-22-01027-i001.jpg)   ![](molecules-22-01027-i002.jpg)   ![](molecules-22-01027-i003.jpg)                             
  **CB-61**                          **CB-83-94**                       **CB-90-98**                                                 
  **Compound with Pkn A Affinity**   **R^1^**                           **R^2^**                           **X**   **R^3^**          **pIC~50~**
  **CB ^a^-61 ^b^ R ^c^ ′**          CH(CH~3~)~2~                       1,2-Dimethoxy-phenylethylamine     \-      \-                −2.699
  **CB-61S ′**                       CH(CH~3~)~2~                       1,2-Dimethoxy-phenylethylamine     \-      \-                −2.699
  **CB-83**                          H                                  C~2~H~5~                           NH      H                 \-
  **CB-84**                          C~6~H~5~                           C~2~H~5~                           NH      H                 \-
  **CB-85**                          H                                  C~2~H~5~                           NH      C~6~H~5~CH~2~     \-
  **CB-86**                          C~6~H~5~                           C~2~H~5~                           NH      C~6~H~5~CH~2~     −1.805
  **CB-88 ′**                        C~6~H~5~                           C~2~H~5~                           NH      (CH~2~)~3~OH      \>−2.107
  **CB-90**                          C~6~H~5~                           C~2~H~5~                           NH      n-C~4~H~9~        −2.071
  **CB-92 ″**                        C~6~H~5~                           C~2~H~5~                           NH      2-OHC~6~H~4~      −2.086
  **CB-93 ′**                        C~6~H~5~                           C~2~H~5~                           NH      4-OHC~6~H~4~      \-
  **CB-94 ″**                        C~6~H~5~                           C~2~H~5~                           NH      3-NH~2~C~6~H~4~   −1.494
  **CB-98 ′**                        3-Methoxy-4-hydroxyphenyl          H                                  \-      \-                \>−2.107
  ---------------------------------- ---------------------------------- ---------------------------------- ------- ----------------- -------------

**^a^ CB**: Chibale's Database; **^b^** Numbering in the Chibale Database (see [SI](#app1-molecules-22-01027){ref-type="app"}); **^c^** Chiral isomerism; ′ Compound with Pkn A and G affinity; ″ Compound with Pkn A and B affinity.

molecules-22-01027-t007_Table 7

###### 

Properties related and selected from the virtual screening to the compounds of [Table 6](#molecules-22-01027-t006){ref-type="table"}.

  Compound                    QPpolz ^d^   SASA ^e^   FOSA ^f^   FISA ^g^   PISA ^h^   WPSA ^i^
  --------------------------- ------------ ---------- ---------- ---------- ---------- ----------
  **CB ^a^-61 ^b^ R ^c^ ′**   46.733       809.665    554.715    61.543     193.408    0.000
  **CB-61S ′**                46.917       824.012    572.502    56.988     194.522    0.000
  **CB-83**                   18.594       409.242    196.278    155.093    57.871     0.000
  **CB-84**                   27.711       506.534    191.029    126.786    188.719    0.000
  **CB-85**                   31.732       572.272    279.927    91.991     200.354    0.000
  **CB-86**                   41.980       693.239    280.021    62.464     350.753    0.000
  **CB-88 ′**                 34.639       641.288    314.312    123.633    203.343    0.000
  **CB-90**                   36.787       661.635    391.158    67.097     203.379    0.000
  **CB-92 ″**                 39.959       668.341    190.827    95.529     381.985    0.000
  **CB-93 ′**                 39.974       673.321    191.826    117.150    364.345    0.000
  **CB-94 ″**                 40.209       675.980    191.376    123.448    361.156    0.000
  **CB-98 ′**                 21.225       452.473    106.409    133.125    139.416    73.522

**^a^ CB**: Chibale's Database; **^b^** Numbering in Chibale's Database (see [SI](#app1-molecules-22-01027){ref-type="app"}); **^c^** Chiral isomerism **^d^ QPpolz**: Predicted polarizability in Å^3^; **^e^ SASA**: Total Solvent-accessible Surface are in Å^2^; **^f^ FOSA**: Hydrophobic component of the SASA (saturated carbons and attached hydrogen); **^g^ FISA**: Hydrophilic component of the SASA (SASA on N, O and H on heteroatom); **^h^ PISA**: Pi (carbon and attached hydrogen) component of the SASA; **^i^ WPS**: Weakly polar component of the SASA (halogens, P and S); ′ Compound with Pkn A and G affinity; **″** Compound with Pkn A and B affinity.
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###### 

Structures, pIC~50~ values of the Pkn A inhibitors.

  Compound   Structure                          pIC~50~
  ---------- ---------------------------------- ---------
  **1**      ![](molecules-22-01027-i004.jpg)   −1.569
  **2**      ![](molecules-22-01027-i005.jpg)   −1.839
  **3**      ![](molecules-22-01027-i006.jpg)   −1.875
  **4**      ![](molecules-22-01027-i007.jpg)   −1.934
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###### 

Structures, pIC~50~ values of the Pkn B inhibitors.

  Compound   Structure                          pIC~50~
  ---------- ---------------------------------- ---------
  **5**      ![](molecules-22-01027-i008.jpg)   0.800
  **6**      ![](molecules-22-01027-i009.jpg)   0.971
  **7**      ![](molecules-22-01027-i010.jpg)   1.066
  **8**      ![](molecules-22-01027-i011.jpg)   1.076
  **9**      ![](molecules-22-01027-i012.jpg)   1.137
  **10**     ![](molecules-22-01027-i013.jpg)   −0.360
  **11**     ![](molecules-22-01027-i014.jpg)   1.638
  **12**     ![](molecules-22-01027-i015.jpg)   −1.200
  **13**     ![](molecules-22-01027-i016.jpg)   1.276
  **14**     ![](molecules-22-01027-i017.jpg)   0.285
  **15**     ![](molecules-22-01027-i018.jpg)   1.187
  **16**     ![](molecules-22-01027-i019.jpg)   −0.375
  **17**     ![](molecules-22-01027-i020.jpg)   0.086
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###### 

Structures, pIC~50~ values of the Pkn G inhibitors.

![](molecules-22-01027-i021)

  C ^a^    R^1^                R^2^   R^3^       R^4^   X   Bond C^3^-X   Bond C^1^-C^2^   pIC~50~
  -------- ------------------- ------ ---------- ------ --- ------------- ---------------- ---------
  **18**   Cyclopropyl         H      H          H      C   C^3^-X        C^1^-C^2^        0.523
  **19**   Cyclohexyl          H      \-         H      O   C^3^-X        C^1^-C^2^        0.167
  **20**   Cyclopropyl         H      \-         H      O   C^3^-X        C^1^-C^2^        0.276
  **21**   Isopropyl           H      --OH       H      C   C^3^=X        C^1^=C^2^        1.523
  **22**   Cyclopropyl         Br     --OH       H      C   C^3^=X        C^1^=C^2^        1.699
  **23**   Methylcyclopropyl   Cl     --OH       H      C   C^3^=X        C^1^=C^2^        1.699
  **24**   Cyclopropyl         Cl     --OCH~3~   Cl     C   C^3^=X        C^1^=C^2^        1.398
  **25**   Ethanol             H      --OH       H      C   C^3^=X        C^1^=C^2^        1.301
  **26**   1,3-Benzodioxole    Cl     --OH       H      C   C^3^=X        C^1^=C^2^        2.000
  **27**   Methylcyclopropyl   H      --OH       H      C   C^3^=X        C^3^=X           1.301

**^a^** C: compound.
